Google’s AI tool struggles in clinical setting

Google’s AI tool for diagnosing diabetic retinopathy is having trouble reading images while it's being tested in an Indian hospital, according to a report by The Wall Street Journal.

The company’s Automated Retinal Disease Assessment (ARDA) tool uses AI to diagnose diabetic retinopathy—a complication of diabetes that can cause blindness—and has shown promise in finding the disease in a variety of studies. However, the tool is struggling with reading images taken in field clinics as its being tested in India.

“While ARDA is effective working with sample data, according to three studies including one published in the Journal of the American Medical Association, a recent visit to a hospital in India where it is being tested showed it can struggle with images taken in field clinics,” the WSJ reported. “Often they are of such poor quality that the Google tool stops short of producing a diagnosis—an obstacle that ARDA researchers are trying to overcome.”

John Quackenbush, a professor of computational biology at the Harvard T.H. Chan School of Public Health, said in the report the tool’s struggle with reading images isn’t unique, since sample images, which algorithms are trained on, can be different from “real-world photos.”

Several AI-driven approaches have recently been successful in detecting diabetic retinopathy with high accuracy. A recent JAMA study detailed an AI-based grading system that successfully diagnosed two patients with the disease. Australian and Brazilian researchers’ AI-driven approach for detecting an early sign of diabetic retinopathy achieved an accuracy rate of more than 98 percent.

To read the full report, click the link below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”